Stock ROQ ROQUEFORT THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Roquefort Therapeutics plc

Equities

ROQ

GB00BMDQ2T15

Investment Management & Fund Operators

Delayed London S.E.
Other stock markets
 04:50:26 2024-06-03 am EDT 		5-day change 1st Jan Change
4.831 GBX -3.37% Intraday chart for Roquefort Therapeutics plc -7.98% -33.36%
May. 23 Windward wins deal; Kodal progresses at Bougouni AN
May. 23 Roquefort Therapeutics plc Announces Executive and Board Changes CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 7.55 8.556 9.363
Enterprise Value (EV) 1 6.65 6.233 8.826
P/E ratio -3.77 x -4.24 x -5.37 x
Yield - - -
Capitalization / Revenue 11,852 x - 46.8 x
EV / Revenue 10,439 x - 44.1 x
EV / EBITDA - - -4,573,667 x
EV / FCF - 5,428,748 x -6,913,062 x
FCF Yield - 0% -0%
Price to Book 1.85 x 1.19 x 1.7 x
Nbr of stocks (in thousands) 71,900 129,150 129,150
Reference price 2 0.1050 0.0662 0.0725
Announcement Date 5/11/22 6/4/23 4/26/24
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales 1 0.000637 - 0.2
EBITDA - - -1.93
EBIT 1 -0.383 -1.634 -1.934
Operating Margin -60,121.98% - -966.82%
Earnings before Tax (EBT) 1 -0.6881 -1.634 -1.932
Net income 1 -0.6881 -1.615 -1.745
Net margin -108,018.05% - -872.27%
EPS 2 -0.0279 -0.0156 -0.0135
Free Cash Flow - 1.148 -1.277
FCF margin - - -638.36%
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 5/11/22 6/4/23 4/26/24
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 - - -
Net Cash position 1 0.9 2.32 0.54
Leverage (Debt/EBITDA) - - -
Free Cash Flow - 1.15 -1.28
ROE (net income / shareholders' equity) - -28.6% -27.5%
ROA (Net income/ Total Assets) - -16.6% -17.4%
Assets 1 - 9.749 10
Book Value Per Share 2 0.0600 0.0600 0.0400
Cash Flow per Share 2 0.0100 0.0200 0
Capex - - 0.05
Capex / Sales - - 27.02%
Announcement Date 5/11/22 6/4/23 4/26/24
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Investment Management & Fund Operators

1st Jan change Capi.
ROQUEFORT THERAPEUTICS PLC Stock Roquefort Therapeutics plc
-33.36% 8.22M
BLACKROCK, INC. Stock BlackRock, Inc.
-4.90% 115B
UBS GROUP AG Stock UBS Group AG
+9.92% 101B
BROOKFIELD CORPORATION Stock Brookfield Corporation
+11.67% 67.41B
APOLLO GLOBAL MANAGEMENT, INC. Stock Apollo Global Management, Inc.
+24.65% 66.1B
BANK OF NEW YORK MELLON CORPORATION (THE) Stock Bank of New York Mellon Corporation (The)
+14.52% 44.58B
AMERIPRISE FINANCIAL, INC. Stock Ameriprise Financial, Inc.
+14.85% 43.37B
3I GROUP PLC Stock 3i Group plc
+19.51% 35.13B
T. ROWE PRICE GROUP INC. Stock T. Rowe Price Group Inc.
+9.42% 26.31B
STATE STREET CORPORATION Stock State Street Corporation
-2.41% 22.77B
Other Investment Management & Fund Operators
  1. Stock Market
  2. Equities
  3. ROQ Stock
  4. Financials Roquefort Therapeutics plc